VistaGen Therapeutics announced that Louis Monti, M.D., Ph.D., a pioneer in the research and development of neuroactive steroids known as “pherines,” including VistaGen’s intranasal drug candidates PH94B for anxiety disorders and PH10 for depression disorders, has joined the Company as Vice President, Translational Medicine. Dr. Monti has served as President and CEO of Pherin Pharmaceuticals since July 2018.